{
  "ticker": "IMU",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02962797",
  "id": "02962797",
  "pages": 3,
  "price_sensitive": false,
  "date": "20250627",
  "time": "0930",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250627/pdf/06l5g31f1vlzss.pdf",
  "summary": "- **First patient dosed in Phase II Neo-POLEM trial** investigating PD1-Vaxx for dMMR/MSI-high colorectal cancer.  \n- **Study design**: Neoadjuvant PD-1 vaccine administered before surgery, targeting ~15% of colorectal cancer patients with this subtype.  \n- **Global recruitment**: Trial conducted in Australia (Queen Elizabeth Hospital) and the UK (collaboration with Cancer Research UK and NHS Trusts).  \n- **Primary endpoint**: Major pathological response rate (tumour shrinkage post-treatment).  \n\n*No material trading or capital markets impact identified (clinical milestone only).*",
  "usage": {
    "prompt_tokens": 1386,
    "completion_tokens": 128,
    "total_tokens": 1514,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-06-26T23:53:54.907599"
}